ArticleCancer immunology, immunotherapy : CII2023
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Wataru Fukuokaya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it